Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Pancreatic Neoplasms 68Breast Neoplasms 58Carcinoma, Non-Small-Cell Lung 36Triple Negative Breast Neoplasms 28Squamous Cell Carcinoma of Head and Neck 15Neoplasms 11Head and Neck Neoplasms 11Lung Neoplasms 10Esophageal Squamous Cell Carcinoma 10Neoplasm Metastasis 7Stomach Neoplasms 6Melanoma 6Adenocarcinoma 6Esophageal Neoplasms 5Cholangiocarcinoma 5Advanced Pancreatic Cancer 5Inflammatory Breast Neoplasms 4Gallbladder Neoplasms 4Fallopian Tube Neoplasms 4Carcinoma 4Small Cell Lung Carcinoma 3Recurrence 3Pathologic Complete Response 3Ovarian Neoplasms 3Neoplasms by Site 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma, Squamous Cell 3Uveal Melanoma 2Uterine Cervical Neoplasms 2

Interventions

durvalumab 1Gemcitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Locally Advanced or Metastatic Solid Tumours × 130-nm albumin-bound paclitaxel × Clear all
NCT04999969 2026-04-30

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

AstraZeneca

Phase 2 Active not recruiting
126 enrolled 30 charts
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡